News

Ideas That Generate Results

The new report by RNCOS by the name of “Global Antibody Drug Conjugate Market Outlook 2020”, predicts that the global ADC market is estimated to reach an approximately value of US$ 12.6 Billion by 2020. The CAGR over the period of 2014-2020 will be around 56%. Currently, there are only two ADCs in the market namely, Adcetris and Kadcyla. These ADCs are also being tested for new indications or in combination with other drugs, so that more benefits can be provided to the patients suffering from different forms of cancer.
 
Apart from these two, there are a number of ADCs being produced by other pharmaceuticals companies which are in the clinical trials. Some of these companies are Immunogen Inc., Immunomedics, Novartis Pharmaceuticals, Bayer Healthcare and Agensys. These companies are developing the ADCs either individually or in collaboration with each other. All these factors point towards a stupendous growth in ADC market in the future.
 
This report is spread in 80 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted.
 
Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM770.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm